Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Anixa and OntoChem are seeking to develop an orally administrable, room-temperature stable, anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19. Two potential compounds were evaluated as well as Remdesivir.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Anixa Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 05, 2021
Details:
Remdesivir is a pro-drug whose metabolite interferes with a SARS-CoV-2 enzyme, RNA-Polymerase. Similarly, Anixa's lead compound interferes with the function of another SARS-Cov-2 enzyme, NSP-15, the noted endoribonuclease.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Anixa Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
Companies have completed the initial in silico screening process of their drug discovery program and have identified an additional specific compound, as well as multiple analogs, that could function as inhibitors of the main protease (Mpro) of the virus.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Anixa Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2020
Details:
The strategic collaboration focuses on discovery and development of anti-viral drug candidates for COVID-19.
Lead Product(s): Antiviral drugs
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Anixa Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 20, 2020